• Profile
Close

Intraocular pressure 1 year after vitrectomy in eyes without a history of glaucoma or ocular hypertension

Clinical Ophthalmology Dec 01, 2017

Fang Y, et al. - Researchers probed into the incidence, risk factors, and treatment of elevated intraocular pressure (IOP) 1 year after vitrectomy in eyes without a history of glaucoma or ocular hypertension. It was discovered that elevated IOP served as a common complication after vitrectomy. A correlation was unveiled between silicone oil tamponade with a greater risk of elevated IOP and it exerted long-term effects on IOP. Additionally, the findings revealed that drugs and surgery were used to control IOP, and few patients required long-term IOP-lowering therapy.

Methods

  • An analysis was conducted of 256 eyes from 256 consecutive patients without a history of glaucoma or ocular hypertension who underwent vitrectomy and were followed up for 1 year.
  • This was followed by an estimation of the incidence of elevated IOP at 1 year after vitrectomy.
  • Researchers undertook a comparative examination of the characteristics of patients with or without elevated IOP with the intention of determining the possible risk factors for elevated IOP.
  • The treatments used to control IOP were recorded and analyzed.

Results

  • Elevated IOP was reported in 50 patients (19.5%) after vitrectomy at the 1-year follow-up.
  • Tamponade was discovered to be a predominant risk factor for elevated IOP (P < 0.05).
  • The cumulative rates of elevated IOP in eyes with air, balanced salt solution, sulfur hexafluoride, perfluoropropane (C3F8), and silicone oil as the tamponade were found to be 0, 10.8%, 5.9%, 19.8%, and 28.4%, respectively (P < 0.05).
  • Occurrences of approximately 68% of cases of elevated IOP were noted within 1 month after vitrectomy.
  • At 1 year after vitrectomy, 29 patients (58.0%) discontinued their IOP-lowering drugs and 21 (42.0%) patients were continuing these drugs.
  • Discontinuation of IOP-lowering drugs was not noted in nearly 65% of ocular hypertension patients who received silicone oil tamponade.
  • A substantially greater rate was disclosed than that of ocular hypertension patients who received C3F8 tamponade (18.2%, P < 0.05).

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay